SoftWave therapy is a real medical technology with FDA clearance, but its marketing often outpaces the evidence behind it. The device, called the OrthoGold OW100S, received FDA 510(k) clearance in October 2022 for three specific uses: relief of minor muscle aches and pains, temporary increase in local blood circulation, and activation of connective tissue. That’s a narrower set of claims than many clinics advertise, and understanding the gap between what’s proven and what’s promoted is key to deciding whether it’s worth your money.
What SoftWave Actually Is
SoftWave is a form of extracorporeal shockwave therapy (ESWT), a category of treatment that’s been used in medicine since the 1980s. The technology sends acoustic pressure waves into tissue, which triggers a biological response: increased blood flow, a local inflammatory reaction that jumpstarts healing, and some evidence of stem cell migration to the treated area. SoftWave’s specific contribution is its “unfocused” wave pattern, which spreads energy over a broader area of tissue rather than concentrating it at a single point.
This matters because older shockwave devices fall into two main categories. Focused shockwave devices concentrate energy at a precise depth (up to 10 to 12 cm into tissue) and are used for conditions like kidney stones and deep tendon injuries. Radial shockwave devices deliver energy from the tip of the device outward, penetrating only about 3.5 cm, with energy dropping off quickly as it disperses. SoftWave positions itself between these two, claiming to deliver therapeutic energy across a wider tissue volume without the discomfort of focused devices. The underlying science of shockwave therapy is well-established; what’s less certain is whether SoftWave’s particular approach delivers meaningfully better results than existing options.
What the FDA Clearance Actually Means
FDA 510(k) clearance is not the same as FDA approval. The 510(k) pathway allows a device to reach the market by demonstrating it is “substantially equivalent” to a device already legally sold, without requiring new clinical trials proving effectiveness. SoftWave’s clearance covers minor muscle aches, temporary blood flow increases, and connective tissue activation. It does not cover many of the conditions clinics commonly market it for, including plantar fasciitis, neuropathy, erectile dysfunction, arthritis, or tissue regeneration.
That doesn’t necessarily mean it doesn’t help with those conditions. It means the manufacturer hasn’t submitted clinical trial data to the FDA proving it does. Clinics using SoftWave for off-label purposes aren’t breaking any laws (doctors can use cleared devices however they see fit), but patients should understand they’re stepping beyond what regulators have evaluated.
The Evidence for Shockwave Therapy
Extracorporeal shockwave therapy as a broader category has a solid evidence base for certain musculoskeletal conditions, particularly plantar fasciitis and calcific tendinopathy. Systematic reviews have found it effective for soft tissue wounds, with treatment protocols typically running one to two sessions per week over one to eight weeks. The biological mechanisms are real: shockwave energy does increase blood flow, reduce pain signaling, and stimulate tissue repair processes.
The problem is that most of this research was conducted using focused or radial shockwave devices, not the specific SoftWave device. SoftWave’s manufacturer and affiliated clinics cite peer-reviewed studies on shockwave therapy generally, including research on stem cell activation and new blood vessel formation. These studies are legitimate, but they don’t always use the same device, energy levels, or protocols that SoftWave clinics employ. When a clinic tells you “SoftWave is backed by research,” ask whether the studies used the OrthoGold device specifically or shockwave therapy in general. The distinction matters.
Safety and Side Effects
Shockwave therapy is genuinely low-risk. The most common side effects are temporary skin redness, mild bruising, and soreness at the treatment site. Less commonly, patients may experience swelling or nerve irritation. According to the International Society for Medical Shockwave Treatment, the main contraindications are having a malignant tumor or a fetus in the treatment area. For high-energy focused devices, additional contraindications include severe clotting disorders and treating near lung tissue, the brain, spine, or growth plates in children.
SoftWave operates at lower energy levels than focused devices, which generally means fewer side effects and less discomfort during treatment. Most patients describe the sensation as a rapid tapping or pulsing, with occasional mild pain over particularly tender areas. No anesthesia is needed, and there’s no downtime afterward.
What Treatment Looks Like
A typical SoftWave treatment plan runs six to twelve sessions. Each session is relatively short, usually 10 to 15 minutes of active treatment. Sessions are spaced one to two times per week, with a full course lasting anywhere from three to eight weeks depending on the condition being treated. Some patients report noticeable improvement after one or two sessions, while others need the full course before seeing results.
The total cost for a complete treatment plan typically falls between $900 and $2,400, or roughly $150 to $250 per session. Many clinics offer a discounted first visit (sometimes around $69) that includes an assessment and a single treatment so you can gauge your response before committing. SoftWave therapy is not covered by Medicare, Medicaid, or private insurance, so you’ll be paying entirely out of pocket.
Red Flags to Watch For
SoftWave itself is a legitimate technology, but the way some clinics market it crosses into misleading territory. Be cautious if a provider claims SoftWave “regenerates” cartilage or reverses arthritis, promises a specific cure rate, or uses testimonials as a substitute for discussing evidence. The stem cell claims deserve particular scrutiny. While shockwave energy can stimulate the body’s own stem cells to migrate toward injured tissue, this is a modest biological signal, not the dramatic regeneration that some marketing implies.
Another warning sign is a clinic that presents SoftWave as a standalone miracle rather than one tool among many. For most musculoskeletal conditions, the best outcomes come from combining treatments like physical therapy, exercise, and lifestyle changes. A provider who recommends SoftWave alongside a broader treatment plan is more credible than one selling it as the only thing you need.
Who Might Benefit Most
SoftWave is most worth considering if you have a chronic soft tissue condition that hasn’t responded well to conventional treatments like physical therapy, anti-inflammatory medications, or corticosteroid injections. Conditions with the strongest shockwave evidence include plantar fasciitis, tennis elbow, calcific shoulder tendinopathy, and certain types of knee pain. If you’re considering it for something more speculative, like neuropathy or erectile dysfunction, know that the evidence is thinner and you’re taking more of a gamble with your money.
The low side-effect profile means there’s little physical risk in trying it. The main risk is financial: spending $1,000 or more on a treatment that may not work for your specific condition. If a clinic offers a single trial session at a reduced cost, that’s a reasonable way to test whether your body responds before committing to the full course.